Atara biotherapeutics announces expanded global tab-cel® partnership with pierre fabre laboratories and third quarter 2023 financial results

Thousand oaks, calif.--(business wire)---- $atra #cart--atara biotherapeutics, inc. (nasdaq: atra), a leader in t-cell immunotherapy, leveraging its novel allogeneic epstein-barr virus (ebv) t-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported recent business highlights including an expanded global partnership with pierre fabre laboratories for tabelecleucel (tab-cel®), financial results for the third quarter 2023, and key upcoming catalysts. “we.
ATRA Ratings Summary
ATRA Quant Ranking